We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
-21.79%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$2.63B
AUM Growth
-$1.11B
Cap. Flow
-$123M
Cap. Flow %
-4.66%
Top 10 Hldgs %
51.48%
Holding
146
New
29
Increased
20
Reduced
29
Closed
45

Top Buys

Rank Stock Value
1
SLDB icon
Solid Biosciences
SLDB
+$123M
2
AMRN
Amarin Corp
AMRN
+$77.8M
3
IOVA icon
Iovance Biotherapeutics
IOVA
+$47.7M
4
ALLO icon
Allogene Therapeutics
ALLO
+$41M
5
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$39M

Top Sells

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$72M
2
CORI
Corium International, Inc.
CORI
+$60.5M
3
ECYT
Endocyte, Inc. Common Stock
ECYT
+$43.4M
4
ISRG icon
Intuitive Surgical
ISRG
+$41.6M
5
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$37.2M

Sector Composition

Rank Sector Weight
1 Healthcare 97.94%
2 Miscellaneous 1.24%
3 Consumer Staples 0.68%
4 Financials 0.08%
5 Consumer Discretionary 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRCA icon
26
Verrica Pharmaceuticals
VRCA
$78.7M
$27.8M 1.06%
341,041
– –
KDMN
27
DELISTED
Kadmon Holdings, Inc.
KDMN
$27.4M 1.04%
13,165,746
– –
RGNX icon
28
Regenxbio
RGNX
$525M
$26.9M 1.02%
645,726
+175,054
+37% +$10.3M
ALDX icon
29
Aldeyra Therapeutics
ALDX
$82.6M
$24.7M 0.94%
3,085,458
– –
VAPO
30
DELISTED
Vapotherm, Inc. Common Stock
VAPO
$24.5M 0.93%
+153,289
New +$22.1M
DOVA
31
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
$23.7M 0.9%
3,125,851
– –
CNCE
32
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$22.8M 0.87%
+1,873,779
New +$25.9M
KOD icon
33
Kodiak Sciences
KOD
$2.07B
$22.3M 0.85%
+3,135,199
New +$27.8M
VRAY
34
DELISTED
ViewRay, Inc.
VRAY
$21.7M 0.83%
3,905,650
+205,650
+6% +$1.54M
NVTA
35
DELISTED
Invitae Corporation
NVTA
$20.6M 0.78%
1,863,406
+2,306
+0.1% +$29.9K
CBAY
36
DELISTED
Cymabay Therapeutics
CBAY
$19.4M 0.74%
2,462,821
-280,000
-10% -$2.67M
ALNY icon
37
Alnylam Pharmaceuticals
ALNY
$31.9B
$18.5M 0.7%
262,241
-935,753
-78% -$72M
NEPT
38
DELISTED
Neptune Wellness Solutions Inc. Ordinary Shares
NEPT
$17.8M 0.68%
6,351
– –
CMTA
39
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
$17.6M 0.67%
+1,500,000
New +$18.7M
ESTA icon
40
Establishment Labs
ESTA
$2.13B
$15.9M 0.6%
614,242
-20,758
-3% -$507K
FOMX
41
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$15.8M 0.6%
4,661,824
+1,554,400
+50% +$6.76M
ADMA icon
42
ADMA Biologics
ADMA
$1.93B
$14.5M 0.55%
6,521,102
– –
RYTM icon
43
Rhythm Pharmaceuticals
RYTM
$6.66B
$13.8M 0.52%
509,186
-155,000
-23% -$4.28M
SAGE
44
DELISTED
Sage Therapeutics
SAGE
$13.1M 0.5%
+147,315
New +$16.9M
LITS
45
Lite Strategy Inc
LITS
$37.1M
$11.6M 0.44%
+220,022
New +$13.6M
PRQR icon
46
ProQR Therapeutics
PRQR
$260M
$11.3M 0.43%
722,523
-38,477
-5% -$706K
MRKR icon
47
Marker Therapeutics
MRKR
$19.5M
$11.1M 0.42%
+200,000
New +$14.6M
AXNX
48
DELISTED
Axonics, Inc. Common Stock
AXNX
$10.9M 0.42%
+751,000
New +$11.2M
IMMU
49
DELISTED
Immunomedics Inc
IMMU
$10.5M 0.4%
700,000
+678,665
+3,181% +$13.5M
MOTS
50
DELISTED
Motus GI Holdings, Inc. Common Stock
MOTS
$9.98M 0.38%
10,702
+1,334
+14% +$1.48M
1
2
3 4 5

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q4 2018 Portfolio in Review

As of Q4 2018, Perceptive Advisors held 146 positions worth $2.63B, down 30% from $3.74B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Perceptive Advisors withdrew a net $123M in Q4 2018, closing 45 positions and reducing 29 holdings. Its most notable exit was Corium International, Inc., an estimated $60.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 93% a quarter earlier, followed by Miscellaneous and Consumer Staples.

Against the trend, Perceptive Advisors opened a new position in Solid Biosciences worth $105M.

  • Perceptive Advisors's largest Q4 2018 buy was Solid Biosciences: 261,815 shares worth $105M.
  • Perceptive Advisors added most to Amarin Corp in Q4 2018, an estimated $77.8M increase.
  • Perceptive Advisors's biggest Q4 2018 reduction was Alnylam Pharmaceuticals, cutting an estimated $72M.
  • Perceptive Advisors fully exited Corium International, Inc. in Q4 2018, selling an estimated $60.5M.
  • Perceptive Advisors's ten largest holdings make up 51% of its $2.63B portfolio in Q4 2018.
  • Perceptive Advisors opened 29 new positions and closed 45 in Q4 2018.
  • Perceptive Advisors's portfolio value fell 30% quarter-over-quarter to $2.63B.

Based on Perceptive Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.